Last reviewed · How we verify
AX251 LAI 135 mg — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AX251 LAI 135 mg (AX251 LAI 135 mg) — Anxo Pharmaceutical Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AX251 LAI 135 mg TARGET | AX251 LAI 135 mg | Anxo Pharmaceutical Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AX251 LAI 135 mg CI watch — RSS
- AX251 LAI 135 mg CI watch — Atom
- AX251 LAI 135 mg CI watch — JSON
- AX251 LAI 135 mg alone — RSS
Cite this brief
Drug Landscape (2026). AX251 LAI 135 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/ax251-lai-135-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab